Curanex Pharmaceuticals (CURX) Operating Expenses (2024 - 2025)
Curanex Pharmaceuticals' (CURX) quarterly Operating Expenses came in at $3.1 million in Q4 2025, up 1998.61% YoY from $147366.0 in Q4 2024, and up 225.09% on a QoQ basis from $951327.0 in Q3 2025.
Curanex Pharmaceuticals (CURX) Operating Expenses (2024 - 2025) Analysis & Trends
Curanex Pharmaceuticals (CURX) has 2 years of Operating Expenses data on file, last reported at $3.1 million in Q4 2025.
- Quarterly Operating Expenses rose 1998.61% year-over-year to $3.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.2 million (changed N/A YoY) and the FY2025 annual result came in at $4.2 million, up 1061.19% from the prior year.
- Operating Expenses advanced to $3.1 million in Q4 2025, from $951327.0 in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $3.1 million in Q4 2025 to a low of $57658.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Curanex Pharmaceuticals | 6.11 Mn | 1.11 Mn | - | 3.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.09 Mn |
| Sep 30, 2025 | 951,327.00 |
| Jun 30, 2025 | 57,658.00 |
| Dec 31, 2024 | 147,366.00 |
| Sep 30, 2024 | 93,295.00 |